Chelation Therapy as a Cardiovascular Therapeutic Strategy: the Rationale and the Data in Review

Area of Science:

• Cardiovascular Medicine
• Toxicology
• Clinical Trials

Background:

• Chelation therapy, primarily for heavy metal detoxification, is controversially applied to coronary artery disease (CAD).
• Patient interest persists despite limited clinical evidence supporting its efficacy in cardiovascular conditions.
• Understanding heavy metal toxicity's cardiovascular impact is crucial for evaluating chelation therapy's role.

Purpose of the Study:

• To appraise the evidence for chelation therapy in treating cardiovascular disease.
• To contextualize its use by examining heavy metal toxicity and cardiovascular health.
• To review clinical trial data on chelation therapy for mitigating heavy metal-related cardiovascular burden.

Main Methods:

• Review of clinical evidence linking heavy metal toxicity to cardiovascular disease.
• Analysis of available clinical trial data, including the Trial to Assess Chelation Therapy (TACT).
• Assessment of chelation therapy's potential benefits and harms in the context of CAD.

Main Results:

• The first Trial to Assess Chelation Therapy (TACT) yielded some significant findings but did not provide conclusive evidence for routine use.
• Limitations in the TACT trial necessitate further investigation.
• Ongoing research, including a second TACT trial, highlights continued interest and debate.

Conclusions:

• Current evidence is insufficient to recommend routine chelation therapy for coronary artery disease.
• Further comprehensive research is essential to determine the true efficacy and safety of chelation therapy for cardiovascular conditions.
• The medical community must address patient pursuit of unproven therapies by thoroughly evaluating their potential impact.